everyone, for Will. and Thanks, thank morning, joining you Good us.
approach As pride achieved. the back we with I on all look have we of XXXX, end
development highlights which this application our application, DNAbilize of therapeutic clinical a treatment usher we to on platform that morning development diseases. month, announced the first an the a for broad development to a BP-XXXX-A new noncancer medicine. technology. deliver begin our the with our exciting promise program of as potential of beyond this metabolic our platform of oncology. continue for DNAbilize utility marks expands I'll era Last Importantly, obesity initiation and DNA-powered This we related the in of of for
will a disease BP-XXXX-A, leading enhanced contributor and sharing the metabolic to Type has diabetes other the protein, which nanoparticle of GRB potential related findings obesity insulin expect to down mechanism of prexigebersen assumptions obesity and enhance for with obesity, regulating a therapeutic insights off we is properties. our to the crucial drug same GRB BP-XXXX-A insulin sensitivity. provide X kick review we studies Type resistance, that BPXXXX-A treat enhancing these BPXXXX-A substance confirm these will expression its to product potential Based X efficacy suppresses the Preclinical X reveal in and major diseases. adapter diabetes. and insulin sensitivity will X research, suggests expect on from and with pathology, into published quarter, The this modified
endometrial, also leading to clinical continue we of cancer, trial with ovarian solid a being patients clinical some breast it with today's is cancer triple-negative cancers endometrial obesity, I/Ib initially tool treat patients. benefit most trial in such evaluate conducted diagnosed at several our the we the centers Beyond and with Patients kit. patients. may recurrent ovarian, This poor have is outcomes, of in often to for and Phase pancreatic advance solid that cancer therapeutic tumors BPXXXX-A and will including provide and challenging hope tumor safety
We dose completion early look potentially readout study forward data to next from this year. cohort and next the
candidate, to with progress now we lead made Turning prexigebersen. have our product the
includes will remission and patients partial of with incomplete decitabine. It with this The complete in previously is AML venetoclax X advance open-label, study X-drug untreated primary multi-center relapsed Phase be cohorts patients II prexigebersen third an amended of to number of hematologic the the who in AML. refractory with refractory continue We patients decitabine A our X X-stage achieve remission, complete includes endpoint complete Stage of treatment venetoclax combination for the combination AML. prexigebersen recovery. study trial in or who of with relapsed hematologic recovery of intolerant cohort remissions AML resistant and which the are with and
BcL-X progress considerable advancing the protein. AML of patients. BPXXXX trial clinical in made refractory BPXXXX relapsed targets our also We I/Ib Phase
RNA in BHX venetoclax. and to messenger prognosis cell AML. However, frontline survival domain, mechanism the driving is correlated treatment is high BcL-X BPXXXX the which drug has and been of with for patients activity is poor not for up with of the diagnosed responsible based of the XX% BcL-X blocking BcL-X for expression cancers, on all
could treatment a received As we that an treatments. treatment. some prevent for the patients provide RNA the overcome mechanisms and AML BPXXXX relapsed, targeting messenger of affect involved resistance By who venetoclax result, in the protein have alternative patients who believe the that BPXXXX including previously may level, venetoclax venetoclax key of venetoclax at
or untreated treatment shown leukemia, has neutralizing works activity and the the chronic patients an against by BHX protein for patients. antiapoptotic and AML Venetoclax is BcL-X improved protein's CLL lymphocytic It domain.
additional with the unless exception to treated invariably with time. tested. incurs evaluable X are require BHX X However, domain dosing with scheduled relapse of be an would total transplantation, in over design, there allogenetic of mutation due for treated patients cell some to X+X A which hematopoietic monotherapy patients toxicity, a cohort a patients dose-limiting standard BPXXXX oftentimes is
starting consisted XX dose meter, and per dose-limiting were a dose first of of The cohort there milligrams toxicity. no square
from patient which for the AML enrollment the was completed initiated data Enrollment of higher cohorts, third options total first of faster Ib relapsed review new in with treatment weeks, the study we efficacy administered cycle of within approved of of with and the X dosing portion need week per continued X doses in The After decitabine over the per is assess completed will milligrams the XX safety is to monotherapy patients. expected XX and projected, meter. of doses than refractory underscores this a treatment square dosing after FDA for X days. BPXXXX over completion its cohorts population. vulnerable commence cohort in combination X weeks BPXXXX The Phase
STATX in protein. liposome-incorporated various made STATX expression STATX as of resistance Activation Its antisense in lung, taxol ovarian, resistance. to ovarian STATX X-FU in progress colon BPXXXX breast migration sensitivity cancers a drug BPXXXX, pathway cancer which malignancies targets cells. and many role transcription the and that let's is such STATX ovarian metastasis oligodeoxynucleotide overexpression novel we've breast the Finally, with aberrant cells proliferation, the a tumor and resistance. and that potential activation processes target. review and including and colorectal regulates stat It's cells therapeutic a tumor factor characterize liver cancer. tumorigenic breast, reduces promotes and of efficiently STATX numerous cancer is made cancer free initiation, in also enhances promotes X-FU. taxol cancer
trace article the pancreatic ovarian in cancer. effect we September, solid highlighting broad types a preclinical In of the Biomedicines. publication of antitumor we BPXXXX describes announced to cancer expect will oligo in plasma have in us drug that testing, period needed a quantities in IND an to peer-reviewed of method After BPXXXX extended in an and we including for FDA. potential final finalize variety therapeutic application The breast, enable safety submission the journal the identified numerous new models tumor complete of for or investigational a detection to
in excited our cancer treatment cutting-edge of validation especially therapy an to launch that We in-human indication has limited this first particularly are challenging options.
With that, Price Anthony sheet review I'll along with highlights. financials the now a Anthony? our to for balance over program of hand brief
